title: Selection of the R263K mutation to dolutegravir in cerebrospinal fluid HIV-1 virus in one patient with HIV-associated neurocognitive disorders.
authors: aDepartment of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes bUnit of Virology, Nice University Hospital, Nice cDepartment of Infectious Diseases, Nice University Hospital, Nice dDepartment of Public Health, Nice University Hospital, Nice, France.
authors: Matteo
authors: M
authors: Vassallo
authors: Anne
authors: A
authors: De Monte
authors: Jacques
authors: J
authors: Durant
authors: Brigitte
authors: B
authors: Dunais
authors: Jacqueline
authors: J
authors: Cottalorda
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D002526:Cerebellar Diseases / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000209:etiology*; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid / Q000150:complications* / Q000188:drug therapy; D019427:HIV Integrase; D019428:HIV Integrase Inhibitors / Q000009:adverse effects*; D015497:HIV-1 / Q000235:genetics*; D006575:Heterocyclic Compounds, 3-Ring / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D019965:Neurocognitive Disorders; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D012008:Recurrence; D019562:Viral Load; D000099226:Dolutegravir
chemical_list: D044966:Anti-Retroviral Agents; D019427:HIV Integrase; D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir